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Abstract 
BACKGROUND: There is a lack of data related to real life, long-term safety, tolerability and compliance of 
omalizumab treatment in asthma patients beyond 6 years. 
AIM: Study aimed to assess safety, tolerability, compliance and all reasons for treatment discontinuation during 
10 years on omalizumab. 
SUBJECT AND METHODS: This is a retrospective, observational study of uncontrolled asthma patients receiving 
omalizumab for the last 10 years. All data were collected from patients’ files (demographics, adverse events, 
comorbidities, compliance index, reasons for discontinuation of omalizumab). Reactions to omalizumab were 
classified as local and systemic, and their severity as mild, moderate or severe. Reactions were either immediate 
(minutes to hours after drug administration) or delayed (after days). Compliance to omalizumab, defined as 
Compliance index (CI), was calculated by comparing milligrams of given to milligrams of prescribed dose/ per 
year.  
RESULTS: Out of 35 patients receiving omalizumab, 15 drop out at different time points mostly due to treatment 
efficacy or appearance of new comorbidities. Patients who continue for the next ten years had mild to moderate 
adverse events related to omalizumab. There was no increased risk of severe adverse events during 10 years on 
omalizumab. Patient’s treatment tolerability, despite mild to moderate adverse events, is in favour of compliance. 
CONCLUSION: Compliance with omalizumab mildly decreased over 10 years but was not affected by severe 
adverse events of treatment or new comorbidities. Although, omalizumab is safe medicine appearance of new 
comorbidities has to be closely followed up. 
 
 
 
 
 
 
Introduction 
 
Asthma is a common, chronic respiratory 
disease affecting 15% of adults and 18% of children in 
Kuwait [1]. Worldwide, approximately 20% of asthma 
patients have severe asthma, of which 20% is 
inadequately controlled [2]. The Global Initiative for 
Asthma (GINA) guidelines recommends a stepwise 
treatment until control is achieved and maintained. 
GINA recommends adding oral corticosteroids (OCS) 
or anti-Immunoglobulin E (IgE) treatment with 
omalizumab in uncontrolled asthma patients [3]. Due 
to well-known severe side effects of oral 
corticosteroids, omalizumab represented promising, 
safer, approach to difficult to control allergic asthma 
[4]. 
Omalizumab was first approved in 2003 to 
treat adults and children 12 years of age and older 
with moderate to severe persistent allergic asthma not 
controlled by inhaled corticosteroids (ICS) and is 
approved lately for children aged ≥ 6 years [5].  
Based on current data it is still unclear when 
omalizumab treatment should be stopped after 
asthma control is achieved [6]. This statement raised 
many issues regarding the long-term safety, 
tolerability, compliance, and possible correlation of 
same during omalizumab treatment.  
There are noted side effects of omalizumab 
recognised by the manufacturer [7] or FDA (The Food 
and Drug Administration) [8]. However, omalizumab 
was found to be in general a well-tolerated therapy 
with frequency and severity of adverse events (AE) 
similar to patients receiving placebo or best available 
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therapy [9]. The study aimed to assess safety, 
tolerability, compliance and all reasons for treatment 
discontinuation during 10 years on omalizumab. 
 
 
Patients and Methods 
 
This was real life, retrospective, observational 
study, conducted at Al Rashed Allergy Centre, the first 
Medical Institution that applied omalizumab for 
uncontrolled, moderate to severe allergic Asthma, 
since 2008 in Kuwait. Inclusion and exclusion criteria 
applied for 35 patients after treatment is stepped up 
on level 5 GINA [10]. All data were collected from 
patients’ files. Patients who stopped with omalizumab 
for different reasons at different time points till the last 
assessment in 2017, were defined as drop out (15 
patients) and a patient who continued (20 patients) as 
an ongoing group. Details of any adverse events 
(whether reported or not in literature) occurred during 
treatment were recorded, as well as details of any 
newly diagnosed comorbidities. Omalizumab was 
administered every 2 or 4 weeks, subcutaneously, at 
the dose calculated based on patients pre-treatment 
total IgE serum level and body weight [11]. Adverse 
events to omalizumab were classified as systemic and 
local reactions, and their severity was classified by 
both physician and patient (mild, moderate, severe) to 
assess eligibility for continuation of treatment. 
Reactions were divided into immediate (few minutes 
to hours after administration drug) and delayed (after 
days). Compliance to omalizumab (Compliance index-
CI) was calculated by comparing milligrams of given 
dose to milligrams of prescribed dose/per year and 
defined as CI ≤ 50% not compliant, 50-75% poor, 76-
89% good and ≥ 90% as high compliance [12].  
 
 
Results 
 
A total of 35 patients started omalizumab 
during 2008. All patients fulfilled GINA stepping up 
criteria [13]. Only one patient required daily use of oral 
corticosteroids prior omalizumab but stopped 
gradually after 6 months of treatment. Thirteen 
patients were receiving omalizumab every 2 while 
resting every 4 weeks. Till assessment in 2017, 15 
patients (11 females) discontinued treatment for 
different reasons at different time points. Demographic 
data of drop out and ongoing treatment group (20 
patients) are presented in Table 1. 
The ongoing group was younger (p < 0.05), 
while gender, BMI and monthly doses of omalizumab 
showed the similar distribution in both groups (p > 
0.05). 
Table 1: Characteristics of patients in ongoing and dropouts 
group 
 On going 
N = 20 
Drop outs 
N = 15 
p value 
Age* in years, mean±SD 41.4 ± 8.95 51.87 ± 16.37 0.0210** 
Female (n; %) 15 (75.0%) 11 (73.3%) 0.7802 
BMI* 30.13 ± 6.78 30.58 ± 4.29 0.8224 
Duration of treatment in years, 
mean±SD 
-Any reason 
-Treatment-related AE 
 
 
- 
- 
 
 
3 ± 1,65 
4 
 
 
ND 
Comorbidities at baseline (n, %) 
Nasal polyps 
Diabetes mellitus type 2 
Hypertension 
Gastroesophageal reflux disease 
Chronis rhinosinusitis 
Seasonal allergic rhinitis 
Hypothyroidism 
Eczema 
Osteoporosis 
Psoriasis 
Obesity (BMI≥30 kg/m
2 
) 
 
9 (45.0%) 
3 (15.0%) 
3 (15.0%) 
6 (30.0%) 
4 (20.0%) 
2 (10.0%) 
3 (15.0%) 
1 (5.0%) 
4 (20.0%) 
1 (5.0%) 
10 (50.0%) 
 
0 (0.0%) 
2 (13.3%) 
0 (0.0%) 
2 (13.3%) 
3 (20.0%) 
1 (6.67%) 
1 (6.67%) 
0 (0.0%) 
1 (6.67%) 
0 (0.0%) 
6 (40.0%) 
 
0.0043** 
1.000 
0.24 
0.42 
1.00 
1.00 
0.62 
1.00 
0.36 
1.00 
0.29 
Comorbidities diagnosed during 
treatment (n, %) 
Diabetes mellitus type 2 
Hypertension 
Psoriasis 
Obesity (BMI≥30 kg/m
2 
) 
Thyroiditis 
Gastroesophageal reflux disease 
Ischaemic heart disease 
Megaloblastic anaemia  
Alzheimer disease 
Cervical tuberculose adenitis 
Liver cirrhosis 
Hypogonadism 
 
 
2 (10.0%) 
2 (10.0%) 
1 (5.0%) 
3 (15.0%) 
1 (5.0%) 
1 (5.0%) 
1 (5.0%) 
2 (10.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
 
 
 
0 (0.0%) 
0 (0.0%) 
1 (6.67%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
1 (6.67%) 
1 (6.67%) 
1 (6.67%) 
1 (6.67%) 
 
 
0.5 
0.5 
1.00 
0.24 
1.00 
1.00 
1.00 
0.5 
0.429 
0.43 
0.43 
0.43 
Index: BMI-body mass index; SD-standard deviation; AE-adverse events; ND-not did; (*)-
Mean age and BMI before the start of omalizumab; (**)-difference was significant. 
 
Among an equal number of presented 
comorbidities in both groups (p > 0.05), nasal 
polyposis was more frequent in the ongoing group (p 
< 0.01), number of new comorbidities diagnosed while 
on omalizumab were similarly noticed in both groups 
(p > 0.05). 
Anaphylaxis related to omalizumab has been 
described as a combination of any of the following: 
angioedema of the throat or tongue, bronchospasm, 
hypotension, syncope, and urticaria [14] which defines 
severe, systemic, treatment stopping reaction.  
On treatment with omalizumab, no immediate 
systemic reaction (anaphylaxis or generalised 
urticaria) was observed in our patients at the 
beginning or during the next ten years. From 35 
patients, 6 had mild to moderate local, and 6 had a 
moderate systemic reaction during the first week after 
omalizumab injection, and all of them continue 
treatment for the next 10 years (Table 2). 
The majority of patients reported adverse 
events from the start of omalizumab while others after 
more than 5 years (e.g. back pain), and few patients 
had occasional (> 3 times per year) occurrence of 
symptoms. All patients who reported any of these side 
effects were evaluated fully for organic and non-
organic causes of symptoms. However, no cause was 
found.  
One 33-year-old female patient stopped 
omalizumab after 4 years (CI = 75%) due to pain in 
the arms and legs up to 5 days after each injection, 
and this has been increasing in intensity with years of 
treatment. 
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Table 2: Treatment-related and other adverse events (AE) in 
patients on omalizumab 
 Patients 
N = 35 (100%) 
Discontinuation for any reason 15 (42.8%) 
Treatment related AEs 12 (34.3%) 
Immediate systemic reaction 0 (0%) 
Immediate local reaction 6 (17.1%) 
Patient with AE non-causing discontinuation 12 (34.3%) 
Other than treatment-related AEs causing discontinuation 
a) poor or very good response on Omalizumab  
b) Psoriasis, newly diagnosed 
c) Alzheimer disease 
d) Liver cirrhosis 
e) Cervical tuberculose adenitis 
f) Hypogonadism 
g) Death during an asthma attack  
 
8 (22.8%) 
1 (2.8%) 
1 (2.8%) 
1 (2.8%) 
1 (2.8%) 
1 (2.8%) 
1 (2.8%) 
Type of treatment-related AE causing discontinuation 
a) pain in arms and legs 
 
1 (2.8%) 
Type of AE non causing discontinuation 
a) pain at the site of injection 
b) pain in arms and legs 
c) pain in legs 
d) back pain 
e) nervousness, fatigue and insomnia 
f) swelling at the site of injection 
g) subjectively perceived increase in hair loss 
h) venous thromalizumabosis 
 
5 (14.3%) 
1 (2.8%) 
2 (5.1%) 
3 (8.6%) 
6 (17.1%) 
2 (5.1%) 
6 (17.1%) 
1 (2.8%) 
Dropouts according to treatment years 
a) after 1 year 
b) after 2 years 
c) after 3 years 
d) after 4 years 
e) after 6 years 
 
1 (2.8%) 
7 (20%) 
3 (8.5%) 
1 (2.8%) 
3 (8.5%) 
 
Other 14 patients stopped omalizumab due to 
other than treatment-related adverse events. Reason 
for discontinuation of omalizumab by a physician, for 
five patients after 2 years, was poor compliance and 
poor effectiveness estimated by asthma control 
parameters [15]. During the first 3 years of treatment, 
three patients showed significant clinical improvement 
and subjectively felt very well, so they decided to stop 
omalizumab. In 5 from 15 patients reason for 
omalizumab discontinuation was the appearance of 
new comorbidity and one female patient died during 
severe asthma attack during the second year on 
omalizumab (deep depressive state after a family 
tragedy, history of near-fatal asthma attacks, CI = 
60%).  
Median CI for drop out group was 72% for all 
years on omalizumab, and for ongoing group 
significantly decreased over 10 years to 80% (Table 
3). Annual Compliance index was higher in period 
from 2008 till 2012, compared to 2013 till 2017 (p < 
0.05, p < 0.0001, p < 0.05, p < 0.001 and p < 0.0001). 
There is no significant difference in CI between 
patients with and without AE in ongoing group (p > 
0.05). 
Table 3: Annual Compliance Index for the ongoing group (n = 
20) 
Year  Compliance 
index 
2008.  1 
2009.  1 
2010.  1 
2011.  0.9 
2012.  0.9 
2013.  0.8 
2014.  0.8 
2015.  0.8 
2016.  0.8 
2017.  0.8 
p-value  < 0.0001* 
*difference was significant. 
 
Discussion 
 
If omalizumab considers years-long treatment 
for moderate to severe uncontrolled asthma, there are 
some concerns regarding tolerability that requires 
close follow up. 
As concluded by Di Bona et al., long-term 
treatment with omalizumab appears remarkably safe 
and well tolerated in a real-life setting. Prolonged 
omalizumab treatment for many consecutive years did 
not increase the risk of side effects, particularly 
anaphylaxis [16]. Data from Randomized Controlled 
Trials (RTC) and post-marketing surveillance showed 
that hypersensitivity reaction to omalizumab are not 
that frequent and anaphylaxis is rare, occurring in 
about 0.09% of patients [17]. Safety data from real life 
observational studies are consistent with the results of 
RCT mostly for short-term studies [18]. Based on our 
data, even the 10-year long treatment with 
omalizumab does not increase the rate of 
anaphylaxis. These results confirm that omalizumab 
has a good safety profile, both in the experimental and 
real-life setting [19].  
Three studies reported adverse events as the 
main cause of treatment discontinuation, without any 
significant differences regarding drop-out rate [20] [21] 
[22]. 
Only one female patient in our study stopped 
omalizumab due to increased, post injection pain in 
arms and legs, lasting up to 5 days. She was satisfied 
with the effectiveness of treatment and tolerated pain 
for 4 years with CI 75%.  
This finding suggests that tolerability is an 
important issue and consequently it has to be carefully 
considered; as evidenced with other treatments, it can 
significantly affect compliance [23]. Most 
observational studies reported a low discontinuation 
rate due to AE over a mean treatment period of 1-2 
years [24] [25] [26] [27] [28] [29] [30], same applied for 
period of 3 and 4 years respectively [31] [32] and 9 
years study reported a 6.6% drop out over a mean 
treatment period of 3.8 years [16]. In our study, local 
reaction at the injection site was the commonest 
adverse event. Pain in arms and legs or legs only 
reported 7.9 % (3 out of 35 patients) and immediate 
local reactions (pain/swelling at the site of injection) 
17.1% patients, but that was not reason enough to 
stop with the treatment during the next 10 years. Di 
Bona et al. reported only one patient with immediate 
local reaction (injection site swelling) [16]. Subjectively 
perceived increase in hair loss in 17.1% of our 
patients is also recognised in different reports [33], but 
it has to be properly assessed and evaluated to be 
labelled as omalizumab induced. Nervousness, 
fatigue and insomnia are reported by 17.1% of 
patients in our study. There is no data about 
nervousness and its correlation with asthma or 
asthma treatment. It is known that chronic diseases 
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such as asthma can cause depression [34]. Fatigue 
and insomnia can be part of depression symptoms 
spectrum [35]. Fatigue and insomnia are also reported 
as mild side effects of omalizumab, and our patients 
reported that it lasted 2 days after injection [36].  
In real-life studies, the drop-out rate ranged 
from 0 to 45.5 %, and in most cases, lack of efficacy 
was responsible for treatment discontinuation [37]. 
Majority of our patients (n = 8) who stopped 
with omalizumab did so because of the poor or 
excellent effect of treatment after the first 2 years, and 
the others due to newly diagnosed comorbidities. In 
individuals with severe asthma, comorbidities are 
common, with the most prevalent being 
gastroesophageal reflux disease (GERD), sinusitis, 
allergic rhinitis and nasal polyposis [38]. Same 
comorbidities were present in our patients before the 
start of omalizumab, but they didn’t affect later 
treatment tolerability and compliance. Although there 
is no confirmed correlation with omalizumab 
treatment, it’s notable that 5 patients in drop out group 
developed new comorbidities over the years on 
omalizumab. A 70-year-old female patient, otherwise 
healthy, stopped omalizumab when diagnosed with 
Alzheimer disease during the sixth year on treatment 
(CI = 90%). There is no data about Alzheimer disease 
in patients on omalizumab, but there are data about 
the increased incidence of Alzheimer in Arab 
countries [39]. A 73-year-old male patient, who had no 
history of smoking, alcohol intake or chronic disease, 
developed liver cirrhosis in full clinical feature during 
the 6
th
 year on omalizumab (CI = 75%) and died few 
months after diagnosis. Male patient (38-year-old) 
with mild improvement on omalizumab stopped the 
treatment when diagnosed with hypogonadism during 
the first year of treatment (CI = 80%), and one female 
patient (39-year-old) was diagnosed with thyroiditis 
(normal hormonal status) after 7 years on 
omalizumab, and she continues with omalizumab 
treatment. We couldn’t find any published reports of 
the liver, thyroid or gonadal hormones issue in 
omalizumab patients. A 34 year old female decided to 
stop omalizumab after 2 years (CI = 90%) when 
diagnosed with cervical tuberculous adenitis.  
There are no studies supporting the 
correlation between omalizumab and tuberculosis, but 
an extra-pulmonary tuberculosis infection rate of 30% 
in Saudi Arabia remains above the global rate [40]. 
Regarding infectious disease, the only low risk of 
parasitic infestation while on omalizumab is reported 
by a specific study carried out in Brazil [41]. A male 
(53 years old) patient stoped omalizumab when 
diagnosed with psoriasis during the first year of 
treatment (CI = 90%). After 7 years of omalizumab 
one (51-year-old), the female patient is also 
diagnosed with psoriasis and continue with treatment. 
Al-Mazeedi et al. conducted a descriptive study to 
determine the extent of psoriasis in Kuwait and the 
risk factors associated with it. The incidence and 
prevalence of psoriasis in Kuwait were calculated to 
be 0.11% and 0.45%, respectively and usual age of 
onset is between 15 and 30 years, although it can 
present at any age [42]. The appearance of psoriasis 
doesn’t seem to be affected by omalizumab or even 
treatment duration.  
Newly diagnosed comorbidities in the ongoing 
group seem not to affect tolerability and compliance. 
We noted 2 patients with newly diagnosed type 2 
diabetes mellitus (after 8 years on omalizumab, older 
than 60 year of age with positive family history for 
diabetes mellitus), two cases of hypertension (patients 
with positive family history for hypertension, both older 
than 60 year), and one gastroesophageal reflux 
disease-GERD (after 4 years of omalizumab 
treatment, history of treated Helicobacter pylori 
infection). In our study, one female patient has 
ischemic heart disease-IHD (49-year-old, history of 
hypertension and transient ischemic brain attack - 
TIA, after 3 years on omalizumab). Although EXCELS 
study's interim safety data showed an excess of 
cardiovascular and cerebrovascular events in the 
patients on omalizumab compared with the asthma 
control group [8] [43], FDA did not recommend any 
changes to the prescribing information (i.e., package 
insert) but did recommend increased awareness [44]. 
There is a question of possible adjustment for asthma 
treatment, omalizumab dosing and parameters for 
follow up, for these high-risk patients.  
In our study, there is also, no newly 
diagnosed malignancies over the 10 year which is 
also consistent with EXCEL study [45].  
Two patients had megaloblastic anaemia 
(females, after 6 years on omalizumab) and one 
(female, 46-year-old, after 9 years on omalizumab) 
had elevated specific liver enzymes with negative 
assessment for infective, autoimmune and malignant 
diseases.  
For noted comorbidities, the bigger cohort 
with long-term follows up is needed, with a closer 
observation on all details that can help in selecting 
patients for omalizumab. Some studies reported that 
about 50% of asthma patients are not compliant with 
the given treatment. The issue becomes even more 
relevant in specific age groups such as children, 
adolescent and elderly [46]. A univocal and 
standardised tool for evaluation of adherence is 
lacking [47]. Another controversial aspect concerns 
the definition of “acceptable adherence”. In some 
large studies, an adherence rate greater than 80 % 
has been considered satisfactory, but a consensus 
about this issue has not been reached. Patients 
requiring treatment with injected drugs, like 
omalizumab, are more easily monitored, as treatment 
administration requires medical supervision [48]. 
Treatment discontinuation can be easily detected and 
considered as a consistent marker of compliance.  
Harjinder et al., the study reported that visit 
compliance does not statistically impact the response 
rate to omalizumab and higher compliance does not 
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correspond to the high response rate [12]. In our 
study, there is a significant decrease in compliance 
expressed as drop-in compliance index from high to 
good for 10 years. In an ongoing group, 12 patients 
had mild to moderate adverse events that should be 
noted as possible reasons for compliance decrease. 
Although there is no significant difference in CI 
between patients with or without reported AE in an 
ongoing group. Efficacy seems to be a more 
significant factor affecting omalizumab treatment 
discontinuation than, other than severe, AE of the 
same medicine. Tolerability of mild to moderate AE in 
favour of treatment efficacy points out an acceptable 
range of CI from 76% and more.  
That emphasises better patient selection and 
devoted follow up by medical stuff during treatment of 
moderate to severe uncontrolled Bronchial Asthma. 
More tool is still required to lead physician, and patient 
as well, from the predicted effect of omalizumab to 
real beneficial one.  
As limitation of our work it can be noted that in 
real-life observational studies is difficult to avoid or 
properly assess bias and conclusions are not easily 
applicable across a generalised population. 
Furthermore, often only a descriptive analysis has 
been provided.  
Nevertheless, to our knowledge, this is first 10 
years study of tolerability, safety and compliance 
which may help in finalising some practical 
suggestions to improve compliance in routine clinical 
practice. 
In conclusion, the most important benefit of 
our study is a long observational period for 
omalizumab treatment. Our results indicate that the 
drug can be administered for many years without 
increased risk of severe adverse events. Continuation 
of treatment despite mild to moderate adverse events 
is due to the patient’s perception of omalizumab 
effectiveness. Therefore, clinicians should discuss 
tolerability issues with their patients as part of a 
strategy aiming at improving compliance. To our 
knowledge, newly diagnosed conditions such as liver 
cirrhosis, thyroiditis and megaloblastic anaemia 
documented after more than 6 years of treatment in 
our patients, are not described in available studies 
and demand closer further observation regarding the 
possible causative role of omalizumab.  
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